Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Vanderbilt University Medical Center, Nashville, Tennessee.
Clin Infect Dis. 2018 May 2;66(10):1504-1510. doi: 10.1093/cid/cix1066.
Streptococcus pneumoniae is considered the leading bacterial cause of pneumonia in adults. Yet, it was not commonly detected by traditional culture-based and conventional urinary testing in a recent multicenter etiology study of adults hospitalized with community-acquired pneumonia (CAP). We used novel serotype-specific urinary antigen detection (SSUAD) assays to determine whether pneumococcal cases were missed by traditional testing.
We studied adult patients hospitalized with CAP at 5 hospitals in Chicago and Nashville (2010-2012) and enrolled in the Etiology of Pneumonia in the Community (EPIC) study. Traditional diagnostic testing included blood and sputum cultures and conventional urine antigen detection (ie, BinaxNOW). We applied SSUAD assays that target serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) to stored residual urine specimens.
Among 1736 patients with SSUAD and ≥1 traditional pneumococcal test performed, we identified 169 (9.7%) cases of pneumococcal CAP. Traditional tests identified 93 (5.4%) and SSUAD identified 76 (4.4%) additional cases. Among 14 PCV13-serotype cases identified by culture, SSUAD correctly identified the same serotype in all of them. Cases identified by SSUAD vs traditional tests were similar in most demographic and clinical characteristics, although disease severity and procalcitonin concentration were highest among those with positive blood cultures. The proportion of pneumonia cases caused by serotypes exclusively covered by PCV13 was not significantly different between the first and second July-June study periods (6.4% vs 4.0%).
Although restricted to the detection of only 13 serotypes, SSUAD testing substantially increased the detection of pneumococcal pneumonia among adults hospitalized with CAP.
肺炎链球菌被认为是导致成人肺炎的主要细菌性病因。然而,在最近一项针对成人社区获得性肺炎(CAP)住院患者的多中心病因学研究中,传统的基于培养的检测和常规尿液检测并未普遍检测到肺炎链球菌。我们使用新型血清型特异性尿液抗原检测(SSUAD)检测方法来确定传统检测是否遗漏了肺炎链球菌病例。
我们研究了在芝加哥和纳什维尔的 5 家医院住院的 CAP 成年患者,并参与了社区获得性肺炎的病因学(EPIC)研究。传统的诊断检测包括血液和痰培养以及常规尿液抗原检测(即 BinaxNOW)。我们应用了针对包含在 13 价肺炎球菌结合疫苗(PCV13)中的血清型的 SSUAD 检测方法,对储存的残余尿液标本进行检测。
在进行了 SSUAD 和至少一项传统肺炎链球菌检测的 1736 名患者中,我们发现了 169 例(9.7%)肺炎链球菌性 CAP 病例。传统检测方法发现了 93 例(5.4%),而 SSUAD 检测方法发现了 76 例(4.4%)额外的病例。在通过培养鉴定的 14 例 PCV13 血清型病例中,SSUAD 正确地鉴定了所有病例的相同血清型。与传统检测方法相比,通过 SSUAD 检测方法发现的病例在大多数人口统计学和临床特征方面相似,尽管阳性血培养病例的疾病严重程度和降钙素原浓度最高。在研究的第一和第二个 7 月至 6 月期间,由仅被 PCV13 覆盖的血清型引起的肺炎病例比例没有显著差异(6.4%对 4.0%)。
尽管 SSUAD 检测方法仅限于检测 13 种血清型,但它大大增加了对 CAP 住院成人肺炎链球菌肺炎的检测。